Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 207

1.

Nonmelanoma Skin Cancer in Childhood and Young Adult Cancer Survivors Previously Treated With Radiotherapy.

Thorsness SL, Freites-Martinez A, Marchetti MA, Navarrete-Dechent C, Lacouture ME, Tonorezos ES.

J Natl Compr Canc Netw. 2019 Mar 1;17(3):237-243. doi: 10.6004/jnccn.2018.7096.

PMID:
30865918
2.

Assessment of Quality of Life and Treatment Outcomes of Patients With Persistent Postchemotherapy Alopecia.

Freites-Martinez A, Chan D, Sibaud V, Shapiro J, Fabbrocini G, Tosti A, Cho J, Goldfarb S, Modi S, Gajria D, Norton L, Paus R, Cigler T, Lacouture ME.

JAMA Dermatol. 2019 Mar 6. doi: 10.1001/jamadermatol.2018.5071. [Epub ahead of print]

PMID:
30840033
3.

The effect of scalp cooling on CIA-related quality of life in breast cancer patients: a systematic review.

Marks DH, Okhovat JP, Hagigeorges D, Manatis-Lornell AJ, Isakoff SJ, Lacouture ME, Senna MM.

Breast Cancer Res Treat. 2019 Feb 26. doi: 10.1007/s10549-019-05169-0. [Epub ahead of print] Review.

PMID:
30806923
4.

Podiatric Adverse Events and Foot Care in Cancer Patients and Survivors Awareness, Education, and Literature Review.

Lacouture ME, Kopsky DJ, Lilker R, Damstra F, van der Linden MHM, Freites-Martinez A, Nagel MPM.

J Am Podiatr Med Assoc. 2018 Nov;108(6):508-516. doi: 10.7547/17-010.

PMID:
30742505
5.

Markers of systemic involvement and death in hospitalized cancer patients with severe cutaneous adverse reactions.

Mori S, Hickey A, Dusza SW, Lacouture ME, Markova A.

J Am Acad Dermatol. 2019 Mar;80(3):608-616. doi: 10.1016/j.jaad.2018.10.039. Epub 2018 Oct 26.

PMID:
30612984
6.

Clinical Characterization of Immunotherapy-Related Pruritus Among Patients Seen in 2 Oncodermatology Clinics.

Phillips GS, Freites-Martinez A, Wu J, Chan D, Fabbrocini G, Hellmann MD, Lacouture ME.

JAMA Dermatol. 2018 Dec 12. doi: 10.1001/jamadermatol.2018.4560. [Epub ahead of print] No abstract available.

PMID:
30540342
7.

Safety of 5α-reductase inhibitors and spironolactone in breast cancer patients receiving endocrine therapies.

Rozner RN, Freites-Martinez A, Shapiro J, Geer EB, Goldfarb S, Lacouture ME.

Breast Cancer Res Treat. 2019 Feb;174(1):15-26. doi: 10.1007/s10549-018-4996-3. Epub 2018 Nov 22. Review.

PMID:
30467659
8.

EGFR and MET Amplifications Determine Response to HER2 Inhibition in ERBB2-Amplified Esophagogastric Cancer.

Sanchez-Vega F, Hechtman JF, Castel P, Ku GY, Tuvy Y, Won H, Fong CJ, Bouvier N, Nanjangud GJ, Soong J, Vakiani E, Schattner M, Kelsen DP, Lefkowitz RA, Brown K, Lacouture ME, Capanu M, Mattar M, Qeriqi B, Cecchi F, Tian Y, Hembrough T, Nagy RJ, Lanman RB, Larson SM, Pandit-Taskar N, Schöder H, Iacobuzio-Donahue CA, Ilson DH, Weber WA, Berger MF, de Stanchina E, Taylor BS, Lewis JS, Solit DB, Carrasquillo JA, Scaltriti M, Schultz N, Janjigian YY.

Cancer Discov. 2019 Feb;9(2):199-209. doi: 10.1158/2159-8290.CD-18-0598. Epub 2018 Nov 21.

PMID:
30463996
9.

Afatinib Therapy: Practical Management of Adverse Events With an Oral Agent for Non-Small Cell Lung Cancer Treatment.

Edwards RL, Andan C, Lalla RV, Lacouture ME, O'Brien D, Sequist LV.

Clin J Oncol Nurs. 2018 Oct 1;22(5):542-548. doi: 10.1188/18.CJON.542-548.

PMID:
30239509
10.

Permanent Chemotherapy-Induced Alopecia in Patients with Breast Cancer: A 3-Year Prospective Cohort Study.

Kang D, Kim IR, Choi EK, Im YH, Park YH, Ahn JS, Lee JE, Nam SJ, Lee HK, Park JH, Lee DY, Lacouture ME, Guallar E, Cho J.

Oncologist. 2019 Mar;24(3):414-420. doi: 10.1634/theoncologist.2018-0184. Epub 2018 Aug 17.

PMID:
30120165
11.

Safety and Efficacy of Re-treating with Immunotherapy after Immune-Related Adverse Events in Patients with NSCLC.

Santini FC, Rizvi H, Plodkowski AJ, Ni A, Lacouture ME, Gambarin-Gelwan M, Wilkins O, Panora E, Halpenny DF, Long NM, Kris MG, Rudin CM, Chaft JE, Hellmann MD.

Cancer Immunol Res. 2018 Sep;6(9):1093-1099. doi: 10.1158/2326-6066.CIR-17-0755. Epub 2018 Jul 10.

PMID:
29991499
12.

Li-Fraumeni Syndrome-related Malignancies Involving the Genitourinary Tract: Review of a Single-institution Experience.

Murray KS, Spaliviero M, Tonorezos ES, Lacouture ME, Tap WD, Oeffinger KC, Vargas HA, Eastham JA.

Urology. 2018 Sep;119:55-61. doi: 10.1016/j.urology.2018.06.008. Epub 2018 Jun 21.

PMID:
29935265
13.

Pruritus Associated with Targeted Anticancer Therapies and Their Management.

Wu J, Lacouture ME.

Dermatol Clin. 2018 Jul;36(3):315-324. doi: 10.1016/j.det.2018.02.010. Review.

PMID:
29929603
14.

Hair disorders in cancer survivors.

Freites-Martinez A, Shapiro J, van den Hurk C, Goldfarb S, Jimenez JJ, Rossi AM, Paus R, Lacouture ME.

J Am Acad Dermatol. 2019 May;80(5):1199-1213. doi: 10.1016/j.jaad.2018.03.056. Epub 2018 Apr 14. Review.

PMID:
29660423
15.

Hair disorders in patients with cancer.

Freites-Martinez A, Shapiro J, Goldfarb S, Nangia J, Jimenez JJ, Paus R, Lacouture ME.

J Am Acad Dermatol. 2019 May;80(5):1179-1196. doi: 10.1016/j.jaad.2018.03.055. Epub 2018 Apr 14. Review.

PMID:
29660422
16.

Osimertinib: A Novel Dermatologic Adverse Event Profile in Patients with Lung Cancer.

Chu CY, Choi J, Eaby-Sandy B, Langer CJ, Lacouture ME.

Oncologist. 2018 Aug;23(8):891-899. doi: 10.1634/theoncologist.2017-0582. Epub 2018 Apr 12. Review.

PMID:
29650685
17.

Endocrine Therapy-Induced Alopecia in Patients With Breast Cancer.

Freites-Martinez A, Shapiro J, Chan D, Fornier M, Modi S, Gajria D, Dusza S, Goldfarb S, Lacouture ME.

JAMA Dermatol. 2018 Jun 1;154(6):670-675. doi: 10.1001/jamadermatol.2018.0454.

18.

Dermatologic Toxicity Occurring During Anti-EGFR Monoclonal Inhibitor Therapy in Patients With Metastatic Colorectal Cancer: A Systematic Review.

Lacouture ME, Anadkat M, Jatoi A, Garawin T, Bohac C, Mitchell E.

Clin Colorectal Cancer. 2018 Jun;17(2):85-96. doi: 10.1016/j.clcc.2017.12.004. Epub 2017 Dec 13.

19.

Taking it in the chin: vitamin K1 for the prevention of acneiform rash.

Lacouture ME.

Ann Oncol. 2018 Apr 1;29(4):796-798. doi: 10.1093/annonc/mdy084. No abstract available.

20.

Single-agent dabrafenib for BRAFV600E-mutated histiocytosis.

Bhatia A, Ulaner G, Rampal R, Hyman DM, Abdel-Wahab O, Durham BH, Dogan A, Ozkaya N, Lacouture ME, Hajdenberg J, Ganzel C, Diamond EL.

Haematologica. 2018 Apr;103(4):e177-e180. doi: 10.3324/haematol.2017.185298. Epub 2018 Feb 22. No abstract available.

21.

The microbial flora of taxane therapy-associated nail disease in cancer patients.

Virgen CA, Belum VR, Kamboj M, Goldfarb SB, Blinder VS, Gucalp A, Lacouture ME.

J Am Acad Dermatol. 2018 Mar;78(3):607-609. doi: 10.1016/j.jaad.2017.08.038. No abstract available.

22.

SJS/TEN 2017: Building Multidisciplinary Networks to Drive Science and Translation.

White KD, Abe R, Ardern-Jones M, Beachkofsky T, Bouchard C, Carleton B, Chodosh J, Cibotti R, Davis R, Denny JC, Dodiuk-Gad RP, Ergen EN, Goldman JL, Holmes JH 4th, Hung SI, Lacouture ME, Lehloenya RJ, Mallal S, Manolio TA, Micheletti RG, Mitchell CM, Mockenhaupt M, Ostrov DA, Pavlos R, Pirmohamed M, Pope E, Redwood A, Rosenbach M, Rosenblum MD, Roujeau JC, Saavedra AP, Saeed HN, Struewing JP, Sueki H, Sukasem C, Sung C, Trubiano JA, Weintraub J, Wheatley LM, Williams KB, Worley B, Chung WH, Shear NH, Phillips EJ.

J Allergy Clin Immunol Pract. 2018 Jan - Feb;6(1):38-69. doi: 10.1016/j.jaip.2017.11.023. Review.

23.

Inflammatory dermatoses, infections, and drug eruptions are the most common skin conditions in hospitalized cancer patients.

Phillips GS, Freites-Martinez A, Hsu M, Skripnik Lucas A, Barrios DM, Ciccolini K, Marchetti MA, Deng L, Myskowski PL, Lee EH, Markova A, Lacouture ME.

J Am Acad Dermatol. 2018 Jun;78(6):1102-1109. doi: 10.1016/j.jaad.2017.12.031. Epub 2017 Dec 19.

PMID:
29273489
24.

Malignancy Risk and Recurrence with Psoriasis and its Treatments: A Concise Update.

Geller S, Xu H, Lebwohl M, Nardone B, Lacouture ME, Kheterpal M.

Am J Clin Dermatol. 2018 Jun;19(3):363-375. doi: 10.1007/s40257-017-0337-2. Review.

PMID:
29260411
25.

First-in-Class ERK1/2 Inhibitor Ulixertinib (BVD-523) in Patients with MAPK Mutant Advanced Solid Tumors: Results of a Phase I Dose-Escalation and Expansion Study.

Sullivan RJ, Infante JR, Janku F, Wong DJL, Sosman JA, Keedy V, Patel MR, Shapiro GI, Mier JW, Tolcher AW, Wang-Gillam A, Sznol M, Flaherty K, Buchbinder E, Carvajal RD, Varghese AM, Lacouture ME, Ribas A, Patel SP, DeCrescenzo GA, Emery CM, Groover AL, Saha S, Varterasian M, Welsch DJ, Hyman DM, Li BT.

Cancer Discov. 2018 Feb;8(2):184-195. doi: 10.1158/2159-8290.CD-17-1119. Epub 2017 Dec 15.

26.

Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group.

Puzanov I, Diab A, Abdallah K, Bingham CO 3rd, Brogdon C, Dadu R, Hamad L, Kim S, Lacouture ME, LeBoeuf NR, Lenihan D, Onofrei C, Shannon V, Sharma R, Silk AW, Skondra D, Suarez-Almazor ME, Wang Y, Wiley K, Kaufman HL, Ernstoff MS; Society for Immunotherapy of Cancer Toxicity Management Working Group.

J Immunother Cancer. 2017 Nov 21;5(1):95. doi: 10.1186/s40425-017-0300-z.

27.

A survey of patient and physician acceptance of skin toxicities from anti-epidermal growth factor receptor therapies.

Tischer B, Bilang M, Kraemer M, Ronga P, Lacouture ME.

Support Care Cancer. 2018 Apr;26(4):1169-1179. doi: 10.1007/s00520-017-3938-7. Epub 2017 Nov 7.

28.

Granuloma annulare associated with immune checkpoint inhibitors.

Wu J, Kwong BY, Martires KJ, Rieger KE, Chung WH, Iyer GV, Lacouture ME.

J Eur Acad Dermatol Venereol. 2018 Apr;32(4):e124-e126. doi: 10.1111/jdv.14617. Epub 2017 Oct 27. No abstract available.

29.

Scalp hypothermia as a preventative measure for chemotherapy-induced alopecia: a review of controlled clinical trials.

Shah VV, Wikramanayake TC, DelCanto GM, van den Hurk C, Wu S, Lacouture ME, Jimenez JJ.

J Eur Acad Dermatol Venereol. 2018 May;32(5):720-734. doi: 10.1111/jdv.14612. Epub 2017 Nov 24. Review.

PMID:
28976026
30.

Pigmentary changes in patients treated with targeted anticancer agents: A systematic review and meta-analysis.

Dai J, Belum VR, Wu S, Sibaud V, Lacouture ME.

J Am Acad Dermatol. 2017 Nov;77(5):902-910.e2. doi: 10.1016/j.jaad.2017.06.044. Epub 2017 Sep 14. Review.

31.

Olmutinib-induced palmoplantar keratoderma.

Chen KL, Cho YT, Yang CW, Sheen YS, Liang CW, Lacouture ME, Chu CY.

Br J Dermatol. 2018 Feb;178(2):e129-e131. doi: 10.1111/bjd.15935. Epub 2017 Dec 18. No abstract available.

32.

Cutaneous Eruptions in Patients Receiving Immune Checkpoint Blockade: Clinicopathologic Analysis of the Nonlichenoid Histologic Pattern.

Kaunitz GJ, Loss M, Rizvi H, Ravi S, Cuda JD, Bleich KB, Esandrio J, Sander I, Le DT, Diaz LA Jr, Brahmer JR, Drake CG, Hollmann TJ, Lacouture ME, Hellmann MD, Lipson EJ, Taube JM.

Am J Surg Pathol. 2017 Oct;41(10):1381-1389. doi: 10.1097/PAS.0000000000000900.

33.

A prospective, randomized, double-blinded, split-face/chest study of prophylactic topical dapsone 5% gel versus moisturizer for the prevention of cetuximab-induced acneiform rash.

Belum VR, Marchetti MA, Dusza SW, Cercek A, Kemeny NE, Lacouture ME.

J Am Acad Dermatol. 2017 Sep;77(3):577-579. doi: 10.1016/j.jaad.2017.03.039. No abstract available.

34.

Novel activating BRAF fusion identifies a recurrent alternative mechanism for ERK activation in pediatric Langerhans cell histiocytosis.

Zarnegar S, Durham BH, Khattar P, Shukla NN, Benayed R, Lacouture ME, Lavi E, Lyden DC, Diamond EL, Dunkel IJ, Abdel-Wahab O.

Pediatr Blood Cancer. 2018 Jan;65(1). doi: 10.1002/pbc.26699. Epub 2017 Jul 27.

35.

Post-reconstruction dermatitis of the breast.

Rosen AC, Goh C, Lacouture ME, Mehrara BJ, Cordeiro PG, Myskowski PL.

J Plast Reconstr Aesthet Surg. 2017 Oct;70(10):1369-1376. doi: 10.1016/j.bjps.2017.05.012. Epub 2017 May 20.

36.

Eruptive Keratoacanthomas Associated With Pembrolizumab Therapy.

Freites-Martinez A, Kwong BY, Rieger KE, Coit DG, Colevas AD, Lacouture ME.

JAMA Dermatol. 2017 Jul 1;153(7):694-697. doi: 10.1001/jamadermatol.2017.0989.

37.

Oral lichenoid reactions associated with anti-PD-1/PD-L1 therapies: clinicopathological findings.

Sibaud V, Eid C, Belum VR, Combemale P, Barres B, Lamant L, Mourey L, Gomez-Roca C, Estilo CL, Motzer R, Vigarios E, Lacouture ME.

J Eur Acad Dermatol Venereol. 2017 Oct;31(10):e464-e469. doi: 10.1111/jdv.14284. Epub 2017 May 8. No abstract available.

38.

Impact of a planned dose interruption of dacomitinib in the treatment of advanced non-small-cell lung cancer (ARCHER 1042).

Kim DW, Garon EB, Jatoi A, Keefe DM, Lacouture ME, Sonis S, Gernhardt D, Wang T, Giri N, Doherty JP, Nadanaciva S, O'Connell J, Sbar E, Cho BC.

Lung Cancer. 2017 Apr;106:76-82. doi: 10.1016/j.lungcan.2017.01.021. Epub 2017 Feb 1.

39.

A phase 1b dose expansion study of the pan-class I PI3K inhibitor buparlisib (BKM120) plus carboplatin and paclitaxel in PTEN deficient tumors and with dose intensified carboplatin and paclitaxel.

Smyth LM, Monson KR, Jhaveri K, Drilon A, Li BT, Abida W, Iyer G, Gerecitano JF, Gounder M, Harding JJ, Voss MH, Makker V, Ho AL, Razavi P, Iasonos A, Bialer P, Lacouture ME, Teitcher JB, Erinjeri JP, Katabi N, Fury MG, Hyman DM.

Invest New Drugs. 2017 Dec;35(6):742-750. doi: 10.1007/s10637-017-0445-0. Epub 2017 Mar 9.

40.

Immune-related alopecia (areata and universalis) in cancer patients receiving immune checkpoint inhibitors.

Zarbo A, Belum VR, Sibaud V, Oudard S, Postow MA, Hsieh JJ, Motzer RJ, Busam KJ, Lacouture ME.

Br J Dermatol. 2017 Jun;176(6):1649-1652. doi: 10.1111/bjd.15237. Epub 2017 Apr 24.

41.

Development of Papulopustular Rosacea during Nivolumab Therapy for Metastatic Cancer.

Bousquet E, Zarbo A, Tournier E, Chevreau C, Mazieres J, Lacouture ME, Sibaud V.

Acta Derm Venereol. 2017 Apr 6;97(4):539-540. doi: 10.2340/00015555-2566. No abstract available.

42.

A Pilot Study of Preoperative Single-Dose Ipilimumab and/or Cryoablation in Women with Early-Stage Breast Cancer with Comprehensive Immune Profiling.

McArthur HL, Diab A, Page DB, Yuan J, Solomon SB, Sacchini V, Comstock C, Durack JC, Maybody M, Sung J, Ginsberg A, Wong P, Barlas A, Dong Z, Zhao C, Blum B, Patil S, Neville D, Comen EA, Morris EA, Kotin A, Brogi E, Wen YH, Morrow M, Lacouture ME, Sharma P, Allison JP, Hudis CA, Wolchok JD, Norton L.

Clin Cancer Res. 2016 Dec 1;22(23):5729-5737. Epub 2016 Aug 26.

43.

reply to the letter to the editor 'Possible determinants of VSL#3 probiotic failure in preventing gastrointestinal adverse events associated with dacomitinib in patients with advanced non-small-cell lung cancer enrolled in ARCHER-1042 trial' by Ceccarelli et al.

Lacouture ME; authors of the publication “A phase II study (ARCHER 1042) to evaluate prophylactic treatment of dacomitinib-induced dermatologic and gastrointestinal adverse events in advanced non-small-cell lung cancer”.

Ann Oncol. 2016 Nov;27(11):2138-2139. Epub 2016 Sep 23. No abstract available.

44.

Dermatological adverse events with taxane chemotherapy.

Sibaud V, Lebœuf NR, Roche H, Belum VR, Gladieff L, Deslandres M, Montastruc M, Eche A, Vigarios E, Dalenc F, Lacouture ME.

Eur J Dermatol. 2016 Oct 1;26(5):427-443. Review.

45.

Dermatologic events from EGFR inhibitors: the issue of the missing patient voice.

Tischer B, Huber R, Kraemer M, Lacouture ME.

Support Care Cancer. 2017 Feb;25(2):651-660. doi: 10.1007/s00520-016-3419-4. Epub 2016 Oct 7. Review.

46.

Stoma care products represent a common and previously underreported source of peristomal contact dermatitis.

Cressey BD, Belum VR, Scheinman P, Silvestri D, McEntee N, Livingston V, Lacouture ME, Zippin JH.

Contact Dermatitis. 2017 Jan;76(1):27-33. doi: 10.1111/cod.12678. Epub 2016 Aug 31.

47.

Characterization and Management of Hedgehog Pathway Inhibitor-Related Adverse Events in Patients With Advanced Basal Cell Carcinoma.

Lacouture ME, Dréno B, Ascierto PA, Dummer R, Basset-Seguin N, Fife K, Ernst S, Licitra L, Neves RI, Peris K, Puig S, Sokolof J, Sekulic A, Hauschild A, Kunstfeld R.

Oncologist. 2016 Oct;21(10):1218-1229. Epub 2016 Aug 10. Review.

48.

Increased Airport Scrutiny by the Transportation Security Administration of a Patient-Passenger Carrying Ammonium Lactate-Containing Moisturizer.

Zarbo A, Ouerfelli O, Klang M, Lacouture ME.

JAMA Dermatol. 2016 Sep 1;152(9):1054-5. doi: 10.1001/jamadermatol.2016.2665. No abstract available.

PMID:
27486908
49.

Recommendations for the Prophylactic Management of Skin Reactions Induced by Epidermal Growth Factor Receptor Inhibitors in Patients With Solid Tumors.

Hofheinz RD, Deplanque G, Komatsu Y, Kobayashi Y, Ocvirk J, Racca P, Guenther S, Zhang J, Lacouture ME, Jatoi A.

Oncologist. 2016 Dec;21(12):1483-1491. Epub 2016 Jul 22. Review.

50.

A phase II study (ARCHER 1042) to evaluate prophylactic treatment of dacomitinib-induced dermatologic and gastrointestinal adverse events in advanced non-small-cell lung cancer.

Lacouture ME, Keefe DM, Sonis S, Jatoi A, Gernhardt D, Wang T, Doherty JP, Giri N, Nadanaciva S, O'Connell J, Sbar E, Piperdi B, Garon EB.

Ann Oncol. 2016 Sep;27(9):1712-8. doi: 10.1093/annonc/mdw227. Epub 2016 Jun 10.

Supplemental Content

Loading ...
Support Center